September 20, 2025CancersOpen Access

Alteration of Prognostic Factors for Patients with Brain Metastases from Lung Cancer Before and After the Introduction of Immune Checkpoint Inhibitors: A Retrospective Single-Institution Study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective study shows improved overall survival in lung cancer patients with brain metastases after ICIs, suggesting enhanced treatment efficacy.

Overall survival significantly improved in patients with brain metastases from lung cancer after immune checkpoint inhibitors were introduced, indicating effective new treatment options.
Median overall survival increased to 10.9 months post-ICI compared to 4.7 months pre-ICI, suggesting a substantial impact of ICIs on treatment outcomes.
Retrospective analysis covered 186 lung cancer patients with brain metastases, indicating shifts in prognostic factors due to evolving therapies over time.
ICIs and molecular targeted therapies emerged as key survival drivers, particularly for patients with squamous cell carcinoma or small cell carcinoma.

Yamamoto et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective study shows improved overall survival in lung cancer patients with brain metastases after ICIs, suggesting enhanced treatment efficacy.